For many practices, the Navigo 4D Fusion Navigation System is not just a clinical innovation—it's a financial growth strategy. With low upfront costs, flexible payment options, and higher reimbursement potential vs. off-site fusion biopsies, Navigo 4D enables urology practices to boost revenue while cutting operational expenses. This blog dives into the financial advantages of adopting in-house MRI-US fusion.
Lowering Costs with Affordable Fusion Biopsy Solutions
Traditional MRI-guided biopsies often require costly hospital-based procedures with higher co-pays for patients than office-based procedures. Navigo 4D eliminates these barriers, making fusion technology accessible to lower-volume sites and private practices.
Seamless Compatibility: Works with most ultrasound systems, TRUS and TP, avoiding expensive new imaging infrastructure.
Flexible Payment Models: Opt for low upfront costs with a pay-per-procedure model (U.S. only), reducing initial investment and optimizing cash flow.
SmartBx Biopsy Management System and Service and Maintenance Included: Increases prostate cancer detection by 25% and allows you to pay as you do biopsies for service, maintenance, support and software upgrades with no minimum volume requirements.
Financial impact: Practices cut overhead costs for scheduling and performing off-site fusion biopsies, while bringing high-value fusion biopsies in-house, boosting profit margins. Dr. Kella, a solo practice urologist at The Urology Place in San Antonio, shares,"The system pays for itself within a year due to increased efficiency and higher reimbursement rates."
Increasing Revenue with Higher Reimbursement Rates
Many urology practices overlook the financial benefits of in-house fusion biopsies. Keeping procedures in-house means greater reimbursement potential.
Higher Reimbursement: Office-based prostate fusion biopsy procedures currently allow the practice to bill more than two times the amount the provider receives in a hospital or ASC setting.1 The office setting typically has higher reimbursement rates due to the site-of-service differential, which accounts for equipment and overhead expenses.
On January 1, 2026, a new set of prostate biopsy codes will be implemented to better reflect the higher costs of various types of prostate biopsies including fusion and transperineal biopsies, and 55700 (the current CPT code for prostate biopsies) will be deleted.2
Higher Case Volume: Efficient in-house scheduling allows practices to do a fusion biopsy in a 15-minute time slot, vs. taking an hour in an ASC or hospital. Thus, you will see more patients weekly, not have holes in your schedule due to delays and cancellations and increase annual revenue.
Practices capture full reimbursement for fusion biopsies, earning significantly more per case compared to off-site procedures. Moving fusion biopsies in-house can drive significant revenue growth through multiple avenues, including billing for the ultrasound technical component and increased case volume. And in addition, there may be additional revenue opportunities in 2026 due to the prostate biopsy coding changes.
Enhancing Efficiency: More Patients, More Revenue
Bringing fusion biopsies in-house with Navigo 4D isn't just cost-effective—It maximizes practice efficiency to drive profitability.
Real-Time Automation: Navigo 4D automatically adjusts for patient movement, and automatically marks biopsies, reducing procedural time and minimizing errors.
Easier Scheduling - Faster Turnaround: No need to coordinate with external facilities, avoiding scheduling delays and patient drop-offs, and improving patient satisfaction.
More Lives Saved, More Revenue Gained: Lower costs expand patient access to MRI-guided biopsies, increasing referrals, detecting high-grade cancers earlier, and improving your treatment revenues and outcomes.
Increased efficiency and automation mean more billable procedures per day, and marketing opportunities to differentiate your practice, thus driving higher revenue growth over time. Dr. Mistry, a urologist at North Austin Urology, notes, "We've seen a 40% increase in biopsy volume since implementing the system, directly impacting our bottom line."
Why Navigo 4D is a Smart Financial Investment
For urology practices aiming to grow revenue, improve efficiency and patient satisfaction,gain a competitive edge, and expand patient access to advanced diagnostics, Navigo 4D Fusion Navigation System is a clear financial win.
Affordable adoption with flexible payment methods
Higher reimbursement potential with existing CPT Codes than off-site biopsies
Increased patient throughput and efficiency
An investment in Navigo 4D can generate an impressive increase in annual revenue and ROI from biopsy procedures alone.
Unlock the Potential of Navigo 4D for Your Practice
Discover how urologists are using Navigo 4D to enhance patient care and boost revenue here. Want to learn more? Schedule a discovery call with UC-Care today and see how Navigo 4D can transform your practice.
References
CPT codes for office based fusion biopsy procedures in 2025 include 55700+76872, with an average national reimbursement of $423.74, whereas physicians only receive $155.91 when performing fusion biopsies at a hospital or ASC site.
American Medical Association. Summary of Panel Actions. May 2024, https://www.ama-assn.org/system/files/may-2024-summary-of-panel-actions.pdf.
Comments